Skip to Content

'
Robert F. Gagel, M.D.

Present Title & Affiliation

Primary Appointment

Head, Division of Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Professor, Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, TX

Education & Training

Degree-Granting Education

1971 Ohio State University, Columbus, OH, BA, Arts-Medicine Program-resulting in both degrees being granted in 1971
1971 Ohio State University, Columbus, OH, MD, Medicine

Postgraduate Training

1973-1975 Fellow in Endocrinology, Tufts-New England Medical Center, Boston, MA, Seymour Reichlin, M.D., Ph.D.
1972-1973 Resident in Medicine, Tufts-New England Medical Center, Boston, MA, William Schwartz, M.D.
1971-1972 Intern in Medicine, Tufts-New England Medical Center, Boston, MA, William Schwartz, M.D.

Board Certifications

1977 Endocrinology and Metabolism
1975 Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Chief, Metabolic Bone Disease Program, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2007-present

Other Appointments/Responsibilities

Member, External Advisory Board, University of Cincinnati Cancer Center, Cincinnati, OH, 2004-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy WA, Gagel RF, Hoff AO. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract 14(9):1108-14, 12/2008. PMID: 19158050.
2. Sherman SI, Angelos P, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Ridge JA, Shah JP, Sisson JC, Tuttle RM, Urist MM, Urist MM. Thyroid carcinoma. J Natl Compr Canc Netw 5, No. 6:568-621, 7/2007.
3. Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, Gagel RF, Evans DB, Perrier ND. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 30(5):643-53, 5/2006. PMID: 16680581.
4. Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, Gagel RF, Arens JF, Evans DB. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198(4):525-34; discussion 534-5, 4/2004. PMID: 15051000.
5. Wohllk N, Becker P, Youlton R, Cote GJ, Gagel RF. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma]. Rev Med Chil 129(7):713-8, 7/2001. PMID: 11552438.
6. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 25(7):914-26, 7/2001. PMID: 11572033.
7. Kikumori T, Cote GJ, Gagel RF. Promiscuity of pre-mRNA spliceosome-mediated trans splicing: a problem for gene therapy? Hum Gene Ther 12(11):1429-41, 7/2001. PMID: 11485634.

Invited Articles
1. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E, Shane E. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-91, 11/2007.
2. Sherman SI, Angelos P, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Ridge JA, Shah JP, Sisson JC, Tuttle RM, Urist MM, Urist MM. Thyroid carcinoma. J Natl Compr Canc Netw 5, No. 6(6):568-621, 7/2007. PMID: 17623612.
3. Jiménez C, Hu MI, Gagel RF. Management of Medullary Thyroid Carcinoma. Endocrinol Metab Clin North Am 37(2):481-96, 2008. PMID: 18502338.

Editorials
1. Cote GJ, Gagel RF. Lessons learned from the management of a rare genetic cancer. N Engl J Med 349:1566-8, 10/2003. PMID: 14561800.

Abstracts
1. Khan MI, Murphy WA, Gagel RF, Hu MI. Long-term bisphosphonate use and risk of subtrochanteric insufficiency fractures: case review. Accepted for ASBMR Annual Meeting, September 11-15, 2009, 9/2009.
2. Gagel RF, Hoff AO, Huang SE, Cote GJ. Calcium and phosphate regulation. ASBMR, 2009.
3. Ye L, Santarpia L, Cote GJ, El-Naggar DK, Gagel RF. Defects of DNA repair pathway occurs in medullary thyroid carcinoma. Presented at MEN2008, Delphi, Greece, 9/2008.
4. Kovacs CS, Kirby EJ, Woodrow JP, Ragel RF, Sims NA. Lack of calcitonin accentuates bone loss during lactation by enhanced osteoclast formation. ASBMR, 9/2008.
5. Santarpia L, Ye L, Cote GJ, El-Naggar AK, Gagel RF. High resolution array-CGH profiling reveals new DNA copy alterations associated with medullary thyroid cancer. Presented at MEN2008, Sept 25-27, Delphi Greece, 2008.
6. Rich TA, Perrier ND, Evans DB, Gagel RF, Marani SK, Matthews J, Peterson SK. Tumor surveillance attitudes and behaviors in patients with multiple endocrine neoplasia Types 1 and 2. Presented at MEN2008, Sept 25-27, Delphi Greece, 2008.
7. Hu MI, Hoff O, Togh BB, Altundag K, Guarneri V, Cui J, Hortobagyi N, Gagel RF. Osteonecrosis of the jaw: long-term follow-up shows variable rate of healing. J Clin Oncol 25, No. 18S:Abstract No. 9061, 6/2007.
8. Wells SA, Gosnell J, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Hou J, Schlumberger M. Vendetanib in metastasis hereditary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol 25, No. 18S:Abstract No. 6018, 6/2007.
9. Jimenez C, Maple S, Sghir F, Gagel RF. Lack of further growth in the size of a 2 pituitary growth hormone producing tumors following initial increase after initiation of pegvisomant therapy. 8th International Pituitary Congress, New York, NY, 6/2003.
10. Vance ML, Cook DM, Gagel RF, HutsonRK, Stewart PM, Svensson J, Burman P, Friend KE. Safety of converting acromegaly patients from slow release octreotide to pegvisomant therapy prior to octreotide clearance: results of a multicenter trial. 85th Annual Meeting of the Endocrine Society, Philadelphia, PA, 6/2003.

Book Chapters
1. Hoff AO, Sherman SI, Gagel RF. Radioiodine treatment in differentiated thyroid malignancy. In: Endocrine Surgery of the Head and Neck. Ed(s) Pellitteri PK, McCaffrey TV. Delmar-Thomson Learning, Inc: Clifton Park, New York, pgs. 201-208, 2003.
2. Gagel RF, Cote GJ. Summary of gene disorders of serum mineral metabolism or skeleton formation. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed. Ed(s) Favus MJ. Lippincott Williams & Wilkins: Philadelphia, pgs. 551-556, 2003.
3. Gagel RF, Shefelbine S, Hayashi H, Cote G. Multiple endocrine neoplasia type 2. In: Principles of Molecular Medicine. Ed(s) Runge MS, Patterson C. Humana Press: New Jersey, pgs. 393-399, 2006.
4. Gagel RF. Introduction to the Care of the Cancer Patient. In: Medical Care Cancer Patients, 1st. Ed(s) Yeung SJ, Escalante C, Gagel RF. B.C. Decker, Inc: Shelton, CT, 1-2, 2009.
5. Hwang JP, Cooper SE, Gagel RF. Mechanisms of complications of malignancy. In: Medical Care of Cancer Patients, 1st ed. Ed(s) Yeung SJ, Escalante C, Gagel RF. B.C. Decker, Inc. Shelton, CT, 3-9, 2009.
6. Hu MI, Yeung SJ, Gagel RF. Endocrine paraneoplastic syndromes. In: Medical Care of Cancer Patients, 1st. Ed(s) Yeung SJ, Escalante C, Gagel RF. B.C. Decker, Inc. Shelton, CT, 194-204, 2009.
7. Yeung SJ, Gagel RF. Endocrine neoplastic syndromes. In: Medical Care of Cancer Patients, 1st. Ed(s) Yeung SJ, Escalante C, Gagel RF. B.C. Decker, Inc. Shelton, CT, 205-208, 2009.
8. Yeung SJ, Gagel RF. Pituitary and adrenal complications in cancer patients. In: Medical Care of Cancer Patients, 1st. Ed(s) Yeung SJ, Escalante C, Gagel RF. B.C. Decker, Inc: Shelton, CT, 237-241, 2009.
9. Yeung SJ, Escalante C, Gagel RF. Survivorship - A Reversal of Fortune. In: Medical Care of Cancer Patients, 1st. Ed(s) Yeung SJ, Escalante C, Gagel RF. B.C. Decker: Shelton, CT, 753-4, 2009.
10. Gagel RF, Marx SJ. Multiple endocrine neoplasia. In: Williams Textbook of Endocrinology. Chapter 40, 11th ed. Ed(s) Larsen PR, Kronenberg HM, Melmed S, Polonsky KS. Saunders: Philadelphia, 1705-46, 2008.
11. Gagel RF. Endocrine manifestations of tumors: "Ectopic" hormone production. In: Cecil Textbook of Medicine, Chapter 148; 23rd ed. Ed(s) Goldman, Ausiello. Saunders Elsevier: Philadelphia, pgs. 1349-53, 2008.
12. Defton LJ, Gagel RF. Medullary Thyroid Carcinoma and Calcitonin. In: Cecil Textbook of Medicine, Chapter 267; 23rd ed. Ed(s) Goldman L, Ausiello D. Saunders Elsevier: Philadelphia, pgs. 1906-10, 2008.
13. Gagel RF, Cote G. Molecular Diagnosis of Bone and Mineral Disorders. In: ASBMR Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th. Ed(s) Rosen CJ, Compston JE, Lian JB. ASBMR: Washington, D.C., 193-6, 2008.
14. Hu MI, Gagel RF. Calcitonin Gene Family of Peptides. In: Principles of Bone Biology. 2, 3rd. Ed(s) Bilezikian JP, Raisz LG, Martin TJ. Academic Press Inc. San Diego, CA, 813-36, 2008.

Books (edited and written)
1. Gagel RF. Ed(s) Yeung SJ, Escalante C, Gagel RF. Medical Care of Cancer Patients., 1st. B.C. Decker Inc. Shelton, CT, 2009.

Letters to the Editor
1. Evans DB, Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. ASBMR JOMS, 2008.

Last updated: 8/5/2009